Toufic Kachaamy, Chief of Medicine and Director of Gastroenterology at City of Hope, shared a post on LinkedIn:
“A major shift in obesity treatment just happened.
The FDA has approved the first pill version of Wegovy, bringing the power of GLP-1 therapy into an oral, once-daily option. This could be a game changer for patients who struggle with injections and for clinicians working to expand access to effective weight-management treatments.
Why it matters:
- Greater convenience and potentially broader adoption with a price tag of 150$ per month for the staring dose
- Fewer barriers for patients hesitant about injectables
- Increased competition in the GLP-1 space, with implications for access and cost
This approval signals how quickly metabolic health care is evolving and how innovation is reshaping chronic disease management.
Obesity is a major risk factor for many cancers including colorectal, endometrial, breast, pancreatic, kidney, and liver cancers. Expanding access to evidence-based obesity therapies is not just about wellness; it is a cancer-prevention and public-health strategy.
My patients often say “I want to do it the natural way and lose weight on my own” what are your thoughts on this statement?
More posts featuring Toufic Kachaamy.